Trial Profile
The Safety and Efficacy of Daclatasvir and Asunaprevir With Chronic HCV Genotype 1b Infection and Chronic Renal Failure
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Jul 2018
Price :
$35
*
At a glance
- Drugs Asunaprevir (Primary) ; Daclatasvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 17 Jul 2018 Status changed from recruiting to completed.
- 21 Mar 2018 Planned number of patients changed from 90 to 21.
- 21 Mar 2018 Planned End Date changed from 1 Dec 2017 to 1 Jun 2018.